Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 7:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Bempedoic Acid 180 MG Oral Tablet Clear all

Conditions: ADPKD (Autosomal Dominant Polycystic Kidney Disease)
Interventions: Bempedoic Acid 180 MG Oral Tablet, Placebo Capsule(s); Drug
Lead sponsor: Kenneth Hallows; Other
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Burlington, Vermont

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions: bempedoic acid; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Tampa, Florida • Louisville, Kentucky • Cincinnati, Ohio

Conditions: Cardiovascular Diseases, NSTEMI, STEMI
Interventions: Bempedoic Acid / Ezetimibe Oral Tablet, Placebo; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Oakland, California

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions: bempedoic acid, placebo; Drug · Other
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 52
States / cities: Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more

Conditions: Hyperlipidemias
Interventions: Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe, Placebos; Combination Product · Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more

Conditions: Hypercholesterolemia, Atherosclerosis, Statin Adverse Reaction
Interventions: Bempedoic acid, Ezetimibe, Placebo; Drug · Other
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Georgetown, Texas

Conditions: Hypercholesterolemia
Interventions: Bempedoic acid; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 8
States / cities: Los Angeles, California • West Covina, California • Boca Raton, Florida + 5 more

Conditions: Healthy Lactating Women
Interventions: Bempedoic Acid 180 MG Oral Tablet, Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Dyslipidemia
Interventions: AZD0780, Ezetimibe, Rosuvastatin, Bempedoic Acid, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Hyperlipidemia
Interventions: ETC-1002, Atorvastatin, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 19
States / cities: Anaheim, California • Los Angeles, California • Northridge, California + 16 more

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions: bempedoic acid, placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 779 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Clearwater, Florida • Georgetown, Texas

Conditions: Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia
Interventions: Bempedoic acid + Ezetimibe FDC Oral Tablet, Ezetimibe 10 mg Oral Tablet, Placebo Oral Tablet, Placebo oral capsule; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Lincoln, California • Miami, Florida • Louisville, Kentucky + 1 more

Conditions: Cardiovascular Diseases, Statin Adverse Reaction
Interventions: Bempedoic acid 180 mg tablet, Matching placebo tablet; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 13,970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 304
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 246 more

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions: ETC-1002, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 48
States / cities: Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more

Search by objective public record fields.

Bempedoic Acid Therapy for Polycystic Kidney Disease

Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)

Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)

A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)